GC Green Cross "Proven Effect of 'Nulapec' in Relapsed and Refractory Multiple Myeloma Patients"

[Asia Economy Reporter Lee Gwan-joo] GC Green Cross announced on the 28th that the investigator-initiated clinical trial results of 'Neurapec,' a treatment for neutropenia, have been published in the international academic journal 'Journal of Hematology & Oncology.'

Neurapec is a second-generation neutropenia treatment independently developed by GC Green Cross. It is an anticancer adjuvant that prevents hematologic side effects caused by a decrease in neutrophil counts in the body, which lowers immunity during chemotherapy in cancer patients.

In this study, 32 patients with multiple myeloma who were either unresponsive to or relapsed after the first-line treatment Bortezomib were analyzed for the anticancer effects of combination therapy with Daratumumab (anti-CD38 monoclonal antibody) and combination chemotherapy (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin, hereafter DCEP), as well as the reduction of hematologic side effects by Neurapec.

Neurapec was administered preventively from the first anticancer therapy, and neutropenia of 'Grade 3' or higher was evaluated at each chemotherapy cycle. The results confirmed that Grade 3 or higher neutropenia (absolute neutrophil count below 1000) was reduced to 8.0?13.8%, compared to previous studies. In prior clinical studies on multiple myeloma patients, Grade 3 or higher neutropenia was observed at rates of up to 35.5% with Daratumumab monotherapy and 91.5% with DCEP monotherapy. When Grade 3 or higher neutropenia occurs, chemotherapy is often delayed or dosages are reduced, which negatively affects patient prognosis.

Additionally, the objective response rate (ORR) of this combination therapy was 67.7%, significantly improved compared to Daratumumab (ORR 29.2?42.1%) and DCEP (ORR 44.4%) monotherapies. In conclusion, by administering Neurapec from the first chemotherapy cycle to prevent neutropenia, chemotherapy could proceed as planned, confirming that Neurapec positively influenced the improvement of ORR in Daratumumab-DCEP combination therapy.

Professor Ko Young-il, head of the study and a hematology-oncology specialist at Seoul National University, stated, "This study showed that preventive administration of Neurapec in chemotherapy with a risk of neutropenia not only improves patients' quality of life but ultimately helps improve prognosis."

Since its launch in 2015, Neurapec's efficacy and safety have been proven in medical practice, leading to expanded prescriptions. Last year, it accounted for 49% of prescriptions based on volume (IQVIA 2021 MAT), making it the most prescribed second-generation neutropenia treatment.

This content was produced with the assistance of AI translation services.